In a brand new Thoracic Cancer paper, Huang et al. examine EGFR-negative lung adenocarcinoma (LUAD) and identify a potential method of accurately distinguishing outcomes and immunotherapy response.
Not only does the work have potential clinical application, but Huang et al. used the GO knowledgebase (as well as other resources like KEGG) to examine M2-like tumor-associated macrophage (TAM) -related prognostic genes. GO analysis demonstrated that M2-like TAM-related genes were mainly enriched in the positive regulation of cell activation, endocytic vesicle, and MHC protein complex binding (Figure 4b).
Read more in the open access paper: Exploring the immune landscape and drug prediction of an M2 tumor-associated macrophage-related gene signature in EGFR-negative lung adenocarcinoma